Meta-Analysis
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Jul 15, 2024; 16(7): 3308-3320
Published online Jul 15, 2024. doi: 10.4251/wjgo.v16.i7.3308
Table 1 Baseline characteristics of includes studies and patients
Ref.
Country
Subjects
Study design
Treatment regimen
Sample size
Age (yr)
Male (%)
Positive of HBV (%)
AFP < 400 ng/mL (%)
Child-Pugh A (%)
BCLC stage A/B/C
EHM (%)
PVTT (%)
Yuan et al[18], 2024ChinaPatients with unresectable HCCRetrospectiveTACE + TKIs + ICIs13959 (50, 67)121 (87.05)115 (82.73)103 (74.10)119 (85.61)0/99/4023 (16.55)31 (22.3)
Sun et al[19], 2024ChinaPatients with advanced HCCRetrospectiveTACE + lenvatinib + sintilimab4055 ± 934 (85.0)30 (75.0)26 (65.0)34 (85.0)0/0/4014 (35.0)29 (72.5)
Sheng et al[20], 2024ChinaPatients with unresectable HCCRetrospectiveTACE + lenvatinib + PD-1 inhibitor11364.48 ± 10.83 95 (84.1)72 (63.7)90 (79.6)88 (77.9)0/54/5915 (13.3)29 (25.7)
Cai et al[17], 2024ChinaPatients with advanced HCCRetrospectiveTACE + lenvatinib + sintilimab3049.4 ± 9.926 (86.7)25 (83.3)NR29 (96.7)NR13 (43.3)NR
Gao et al[21], 2023ChinaPatients with advanced HCCRetrospectiveTACE + TKIs + ICIs4152 (46, 57)35 (85.4)29 (70.7)9 (22.0)32 (78.0)0/11/3010 (24.4)29 (70.7)
Li et al[22], 2023ChinaPatients with advanced HCCProspectiveTACE + TKIs + camrelizumab8756 (34, 75)81 (93.1)75 (86.2)51 (58.6)51 (58.6)NR/NR/6943 (49.4)65 (74.7)
Hu et al[44], 2023ChinaPatients with unresectable HCCRetrospectiveTACE + TKIs + ICIs9852 (42, 62)87 (88.8)85 (86.7)NR75 (76.5)0/12/8649 (50.0)14 (14.3)
Zhang et al[23], 2024ChinaPatients with unresectable HCCRetrospectiveTACE + TKIs + ICIs54≤ 60: 38 (72.5); > 60: 16 (27.5)46 (85.0)53 (98.1)26 (48.1)54 (100)0/23/3119 (35.2)NR
Wu et al[24], 2024ChinaPatients with unresectable HCCProspectiveTACE + lenvatinib + camrelizumab5554 (46, 62)45 (81.8)27 (49.1)23 (41.8)55 (100)0//12/4310 (18.2) 37 (67.3)
Gao et al[25], 2023ChinaPatients with TACE-refractory HCCRetrospectiveTACE + lenvatinib + PD-1 inhibitor5757.5 ± 9.445 (78.9)43 (75.4)NR34 (59.6)0/17/4024 (42.1)NR
Lu et al[26], 2023ChinaPatients with unresectable HCCRetrospectiveTACE + donafenib + toripalimab8151.9±12.465 (80.2)54(66.7)NR46 (56.8)0/22/59NRNR
Pan et al[27], 2023ChinaPatients with unresectable HCCRetrospectiveTACE + TKIs + ICIs49< 65: 38 (77.6); ≥ 65: 11 (22.4)46 (93.9)41 (83.7)21 (42.9)40 (81.6)5/14/306 (12.2)27 (55.1)
Wu et al[28], 2023ChinaPatients with BCLC-defined stage C HCCRetrospectiveTACE + lenvatinib + camrelizumab5753.18 ± 9.2549 (86.0)44 (77.2)25 (43.9)52 (91.2)0/0/5723 (40.4)NR
Wang et al[29], 2023ChinaPatients with unresectable HCCRetrospectiveTACE + lenvatinib + PD-1 inhibitor4554 (18, 79) 42 (93.33)42 (93.33) 13 (28.89)NRNR18 (40.0)20 (44.44)
Xin et al[30], 2023ChinaPatients with unresectable HCCRetrospectiveTACE + lenvatinib + PD-1 inhibitor6057.5 (26, 76)54 (90.0)56 (93.4)32 (53.3)NR0/21/3918 (30.0)28 (46.7)
Wang et al[31], 2023ChinaPatients with unresectable HCCRetrospectiveTACE + lenvatinib + PD-1 inhibitor4655.54 ± 11.9241 (89.1)42 (91.3)18 (39.1)38 (82.6)0/8/3824 (52.2)NR
Sun et al[32], 2023ChinaPatients with advanced HCCRetrospectiveTACE + TKIs + camrelizumab7053.8 ± 10.458 (82.9)54 (77.1)30 (42.9)57 (81.4)NRNRNR
Ju et al[33], 2021ChinaPatients with unresectable HCCRetrospectiveTACE + apatinib + camrelizumab56 52 (26, 75)46 (82.1)48 (85.7)NR43 (76.8)0/13/43NRNR
Cai et al[34], 2022ChinaPatients with advanced HCCRetrospectiveTACE + lenvatinib + PD-1 inhibitor4151.9 ± 10.337 (90.2)35 (85.4)20 (48.8)37 (90.2)NR17 (41.5)NR
Li et al[35], 2022ChinaPatients with unresectable HCCRetrospectiveTACE + lenvatinib + PD-1 inhibitor11453 (24, 79)102 (89.5)102 (89.5)NR111 (97.4)3/42/6923 (20.2)NR
Teng et al[36], 2022ChinaPatients with unresectable HCCRetrospectiveTACE + lenvatinib + PD-1 inhibitor5356.9 (37, 75)45 (84.9)45 (84.9)35 (66.0)34 (64.2)0/23/3042 (79.2)NR
Qu et al[37], 2022ChinaPatients with unresectable HCCRetrospectiveTACE + lenvatinib + PD-1 inhibitor5651 (24, 82)51 (91.1)43 (76.8)34 (60.7)53 (94.6)0/17/3929 (51.8)NR
Yang et al[38], 2022ChinaPatients with unresectable HCCRetrospectiveTACE + TKIs + ICIs5359 ± 10.645 (85.0) 47 (89.0)34 (64.0)34 (64.0)2/29/22NRNR
Yang et al[39], 2021ChinaPatients with unresectable HCCRetrospectiveTACE + TKIs + ICIs3157.5 ± 9.425 (80.6)26 (83.9)23 (74.2)27 (87.1)2/18/11NRNR
Liu et al[45], 2021ChinaPatients with advanced HCCRetrospectiveTACE + lenvatinib + camrelizumab2257.7 ± 9.917 (77.3)15 (68.2)7 (31.2)16 (72.7)0/12/108 (36.4)11 (50.0)
Wu et al[40], 2021ChinaPatients with unresectable HCCRetrospectiveTACE + lenvatinib + Anti-PD-1 antibodies 6257 (23, 75)56 (90.3)57 (91.9)30 (48.4)62 (100.0)6/21/356 (9.7)15 (24.2)
Cao et al[41], 2021ChinaPatients with unresectable HCCRetrospectiveTACE + lenvatinib + sintilimab52≤ 65: 40 (76.9); > 65: 12 (23.1) 45 (86.4)47 (90.4)34 (65.4)46 (88.5)0/13/3921 (40.4)NR
Zheng et al[42], 2020ChinaPatients with advanced TACE-refractory HCCRetrospectiveTACE + sorafenib + ICIs22< 55: 10 (45.45); ≥ 55: 12 (54.55)19 (86.36)17 (77.27)7(31.82)13 (59.03)0/11/117(31.82)7(31.82
Chen et al[43], 2022ChinaPatients with unresectable HCCRetrospectiveTACE + lenvatinib + pembrolizumab7058 (36, 69) 37 (52.9)38 (54.3)25 (35.7)70 (100.0)0/47/23NRNR